Jeon et al. demonstrated that luteolin combined with celecoxib synergistically suppressed tumor growth in multiple breast cancer cell lines, mediated through Akt inhibition and cell-line–specific modulation of ERK signaling [103]. Here, AKT1 is linked to neoplasm.